Bioprogress Future2

daveperry - 22 Dec'05 - 20:01 - 8541 of 8548
You're only seeing 1/2 the picture. Dexo BioPharm (aka Dexo SA) have their own products, which you quoted, and we'll roll out Xgel against all those but they are specialist products in niche fields.

Then, completely seperate to that, we have the JV with Crescent who have their own set of products which we'll roll out Xgel with. I beleive that Crescent's product line holds more potential for us which is why I'm delving into find out their details.

It would seem to me that with Crescent, we're going to try to capture a larger share of the NHS's appetite for generic drugs.

Aside from that, with Dexo Biopharm, we're going to rollout their products, but more importantly, they'll most probably become the pushers of wafertab products, as they have the expertise of introducing innovative, novel products in the french market. First France and then the world. (Wasn't that Germany's moto?)

RT has set in motion two seperate attacks (war puns again) on getting tabwrap and wafertab products onto the shelves.

Inghu